The relationship between relative telomere length and anti-tuberculosis drug-induced hepatitis : A case-control study.

Abstract

AIM:

Anti-tuberculosis drug-induced hepatitis (AT-DIH) is a common and serious adverse drug reaction of tuberculosis treatment. Evidence demonstrated that many factors could affect the occurrence of AT-DIH, such as ageing, smoking, alcohol, oxidative stress, etc., while these factors could also promote telomere shortening. Therefore, relative telomere length (RTL) is indirectly related to the occurrence of AT-DIH. The present study aimed to explore and validate this relationship in Chinese tuberculosis patients.

METHODS:

A 1:4 matched case-control study was undertaken using 202 AT-DIH cases and 808 controls. Logistic regression models were used to estimate the association between RTL and AT-DIH with odds ratios (ORs) and 95% confidence intervals (CIs). The area under receiver operating characteristic curve (AUC) was calculated to estimate the discriminative performance for distinguishing AT-DIH cases from controls.

RESULTS:

The average RTL in AT-DIH cases was significantly shorter than that in controls (1.24 vs. 1.46, P=0.002). Patients with longer RTL were at a reduced risk of AT-DIH (OR=0.79, 95% CI: 0.66-0.94, P=0.009), and a dose-response relationship also existed between RTL and lower AT-DIH risk (P for trend=0.012). Under the optimal RTL cut-off value of 1.22, the corresponding AUCs were 0.57 (95% CI: 0.53-0.62, P=0.001) in the univariate model and 0.62 (95% CI: 0.57-0.66, P<0.001) in the multivariate model.

CONCLUSION:

This study showed that the shorter the RTL, the higher the risk of AT-DIH during an anti-tuberculosis treatment. The short RTL could potentially serve as a risk factor or a predictive test of the hepatotoxic risk associated with anti-tuberculosis treatments.

• Authors: Wenpei Liu, Nannan Wang, Jia Zhu, Meiling Zhang, Lihuan Lu, Hongqiu Pan, Xiaomin He, Honggang Yi, Shaowen Tang
• Journal: Therapie (Therapie) 2023 May-Jun Vol. 78 Issue 3 Pg. 259-266 ISSN: 1958-5578 [Electronic] France
• PMID: 35710461 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Chemical References

• Antitubercular Agents

Topics

• Humans
• Case-Control Studies
• Antitubercular Agents (adverse effects)
• Risk Factors
• Hepatitis
• Telomere